BioPharmSignal logoBioPharmSignal

Biotech News

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

Sight Sciences (SGHT)Sight SciencesEarnings

MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today

Related news

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

ACHCAcadia Healthcare2026-11-04 21:05 EST

Acadia Healthcare Announces Third Quarter 2026 Results and Raises Full Year 2026 Financial Guidance

PRCTPROCEPT BioRobotics2026-11-04 21:05 EST

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

IARTIntegra LifeSciences2026-10-02 12:05 EST

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

ICUIICU Medical2026-11-05 21:05 EST

ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range

PLSEPulse Biosciences2026-11-05 21:05 EST

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

STIMNeuronetics2026-11-04 12:50 EST

Neuronetics Reports Third Quarter 2026 Financial and Operating Results

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

AORTArtivion2026-10-22 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results

View all latest news

Sight Sciences

Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a...

Recent company news

SGHTSight Sciences2026-11-05 21:05 EST

Sight Sciences to Present at Two Upcoming Investor Conferences

SGHTSight Sciences2026-11-05 13:00 EST

Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids

SGHTSight Sciences2026-11-04 21:05 EST

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

SGHTSight Sciences2026-10-01 11:05 EST

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

Stock data

Close
9.76 USD
Market cap
236.14M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States